,
Akhtar, Aemal
Giardinelli, Luana
Bawaneh, Ahmad
Awwad, Manar
Naser, Hadeel
Whitney, Claire
Jordans, Mark J. D.
Sijbrandij, Marit
Bryant, Richard A.
Funding for this research was provided by:
National Health and Medical Research Council (1142605)
Horizon 2020 (733337)
Article History
Received: 6 February 2020
Accepted: 5 March 2020
First Online: 26 March 2020
Ethics approval and consent to participate
: The project has been approved locally by the institutional review board at the King Hussein Cancer Centre in Amman, Jordan, and the University of New South Wales Human Research Ethics Committee. Informed consent entails a two-step procedure: 1) informed consent to conduct the screening and 2) informed consent for taking part in the gPM+ trial. The latter is only required for participants meeting the inclusion criteria following screening. For each step, participating respondents will be asked to complete a written consent form. For participants who are illiterate, witnessed oral consent will be collected, in line with recommendations from the WHO.
: Not applicable.
: The authors declare that they have no competing interest.